Dermata Therapeutics Insider Buy Signals Confidence, Drives Drug and Skincare Strategy
Dermata Therapeutics sees CEO buy‑back boost as signal of confidence; insider purchase fuels rare‑disease drug, direct‑to‑consumer skincare, and market‑access strategy.
5 minutes to read